Application of IGFBP-2 (insulin-like growth factor binding protein 2) in preparation of acral leucoderma color recovery medicine
IGFBP-2 promotes the differentiation of dermal stem cells into melanocytes, and combined with 308nm excimer phototherapy, the problem of long and poor recolor treatment cycle of acrolith vitiligo is solved, achieving significant recolor effect.
Patent Information
- Application Number
- CN202411020751.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-12-03
AI Technical Summary
The treatment cycle for acrolith vitiligo is long and has poor results, especially in exposed areas such as hands and feet. Existing treatment methods are difficult to effectively promote the regeneration of melanocytes and the recolor of skin lesions.
By studying the effect of insulin-like growth factor binding protein-2 (IGFBP-2) on human dermal stem cells, promoting their differentiation into melanocytes, using the RhoA/YAP signaling pathway mechanism of IGFBP-2, a kind of use for limbs was developed to develop Complex drugs for vitiligo, combined with 308nm excimer phototherapy, significantly improve the therapeutic effect.
IGFBP-2 does not affect cell activity at safe concentrations, significantly upregulates the expression of related proteins, and promotes the differentiation of dermal stem cells into melanocytes. Clinical trials show that its combined use with phototherapy can significantly improve the complex color effect of acrolith vitiligo, which is better than using alone. Phototherapy.
Smart Images

Figure CN119055744A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a new use of insulin-like growth factor binding protein-2 (IGFBP-2) in the preparation of a dummy vitiligo repigmentation drug. Background Art
[0002] Vitiligo is a common skin depigmentation disease caused by the selective destruction of melanocytes (MC). The global incidence rate is about 0.5-2%, which is increasing year by year. [1] The clinical classification of vitiligo is segmental, non-segmental, mixed and undetermined. Among them, non-segmental vitiligo includes scattered, generalized, face and neck, acral and mucosal types. [2] Acrofacial vitiligo lesions often occur on exposed areas such as the hands, feet, and around the mouth, seriously damaging the patient's quality of life and physical and mental health. [3] . Since the lesions of acrofacial vitiligo are located in exposed and active parts of the human body, the treatment is more difficult, and more research is needed to explore new treatment targets and strategies. Currently, there are different treatment methods for acrofacial vitiligo, including drug therapy, physical phototherapy, and transplant surgery, but the long treatment cycle and poor re-pigmentation effect are still thorny problems that need to be solved. [4] .
[0003] Clarifying the mechanism of repigmentation in acrofacial vitiligo will help explore new therapeutic targets and is an important research direction for vitiligo. The repigmentation of vitiligo lesions is closely related to the regeneration of melanocytes. Due to the lack of hair follicles in the acrofacial area, it is extremely difficult to repigment vitiligo lesions. Therefore, melanocyte precursor cells / dermal stem cells in the dermis are a reliable source of natural melanocytes in the acrofacial lesions of vitiligo. Dermal stem cells are a type of neural crest-like stem cells that originate from the somitic mesoderm and can express related markers of neural crest stem cells. Studies have shown that the Hippo-YAP signaling pathway plays an important role in regulating neural crest development. During neural crest development, Yes-Associated Protein (YAP) regulates the proliferation and differentiation of neural crest cells, affects the morphogenesis of the neural crest and the fate trajectory of the cells, and promotes their differentiation and maturation into melanocytes. [5-7] The Hippo / YAP pathway may also play an important role in the differentiation of dermal stem cells into melanocytes.
[0004] IGFBP-2 is an IGF-binding protein that binds to and regulates the biological activity of IGF outside the cell. At the same time, IGF is an important class of cell growth factors that promote cell proliferation and growth by binding to IGF receptors on the cell surface. Cui et al. [8]Studies have found that IGFBP-2 can recognize m6A on YAP mRNA and promote the translation of mRNA. YAP regulates the expression of ErbB2 by promoting the enrichment of TEAD4 in the ErbB2 promoter region. Therefore, IGFBP-2 can promote the expression of ErbB2, thereby enhancing the proliferation, invasion and migration of colorectal cancer cells and inhibiting cell apoptosis. Rozengurt et al. [9] reported that IGFBP-2 is a regulatory gene of YAP / TEAD. IGFBP-2 can promote the nuclear translocation and activation of YAP / TAZ, affect cell differentiation and proliferation, and is associated with poor survival in patients with pancreatic ductal adenocarcinoma. Nader et al.
[10] It was found that IGFBP-2 may also regulate cell proliferation by affecting the activity of Hippo signaling pathway members (such as MST1 / 2 and LATS1 / 2), thereby affecting the activity of YAP / TAZ. Current studies have shown that IGFBP-2 is closely related to the Hippo / YAP signaling pathway, but there are no reports on IGFBP-2 improving the complex color of acrofacial vitiligo. The present invention studies the effect of IGFBP-2 on the biological characteristics of human dermal stem cells, explores new ways to promote the directional differentiation of human dermal stem cells into melanocytes, and explains the molecular mechanism of IGFBP-2 promoting the differentiation process from a cytological level, which is used for the clinical treatment of acrofacial vitiligo.
[0005] References:
[0006] [1] Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020; 236 (6): 571-592. [2] Rodrigues M, Ezzedine K, Hamzavi I, et al. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017Jul; 77 (1): 1-13.
[0007] [3]Di Bartolomeo L,Custurone P,Irrera N,et al.Vitiligo and MentalHealth:Natural Compounds'Usefulness.Antioxidants(Basel).2023Jan 11;12(1):176.
[0008] [4]Jafarzadeh A,Pour Mohammad A,Khosravi M,et al.A systematic reviewof case series and clinical trials investigating systemic oral or injectabletherapies for the treatment of vitiligo.Skin Res Technol.2024Mar;30(3):e13642.
[0009] [5]Bhattacharya D,Azambuja AP,Simoes-Costa M.Metabolic ReprogrammingPromotes Neural Crest Migration via Yap / Tead Signaling.Dev Cell.2020Apr20;53(2):199-211.e6.
[0010] [6]Sun X,Ren Z,Cun Y,et al.Hippo-YAP signaling controls lineagedifferentiation of mouse embryonic stem cells through modulating theformation of super-enhancers.Nucleic Acids Res.2020Jul 27;48(13):7182-7196.
[0011] [7]Kumar D,Nitzan E,Kalcheim C.YAP promotes neural crest emigrationthrough interactions with BMP and Wnt activities.Cell Commun Signal.2019Jun22;17(1):69.[8]Cui J,Tian J,Wang W,et al.IGF2BP2 promotes the progression ofcolorectal cancer through a YAP-dependent mechanism.Cancer Sci.2021Oct;112(10):4087-4099.
[0012] [9] Rozengurt E, Sinnett-Smith J, Eibl G. Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival. Signal Transduct Target Ther. 2018Apr 20; 3:11.
[0013]
[10] Abou Nader N, Blais St-Jean G, et al. Effect of Inactivation ofMst1 and Mst2 in the Mouse Adrenal Cortex. J Endocr Soc. 2022 Sep16;7(1):bvac143. Summary of the invention
[0014] The purpose of the present invention is to provide a new use of insulin-like growth factor binding protein-2 (IGFBP-2) in the preparation of a dummy vitiligo repigmentation drug.
[0015] The present invention uses cell model experiments to confirm that IGFBP-2 does not affect the cell activity of human dermal stem cells at a safe concentration, and can upregulate the expression of differentiation and melanogenesis-related proteins YAP, RhoA, TAZ, PAX3 and MITF. At the same time, IGFBP-2 effectively promotes dermal stem cell differentiation and depends on the RhoA pathway and YAP. The present invention discloses a method for promoting the directional differentiation of dermal stem cells into melanocytes using IGFBP-2, and explains the specific mechanism from a cytological level, which can be used as a potential treatment for acral vitiligo.
[0016] The specific experimental research of the present invention includes:
[0017] (1) Human dermal stem cell culture: Human primary dermal stem cells were selected and cultured at 2×10 5 The cells were inoculated at a density of 1:100 / mL in T25 and cultured at 37°C. The culture medium (DMEM / F12+B27+bFGF+EGF+double antibodies (streptomycin, penicillin)) was changed regularly. The cells were passaged once according to their growth status (the degree of confluence was 70-80%).
[0018] (2) IGFBP-2 intervention: Human IGFBP-2 was used and dissolved in different concentrations using the above culture medium according to the dosage requirements of subsequent experiments. The original culture medium was used to replace the original culture medium for intervention for 48 hours. After the intervention, cell samples were taken for subsequent experiments.
[0019] (3) Screening of safe dose of IGFBP-2: Cell morphology was observed using an optical microscope, cell activity and apoptosis were determined using the CCK-8 method, and the effects of different concentrations of IGFBP-2 on cell activity after 48 hours of intervention were detected. The concentration of IGFBP-2 that had no effect on the activity of human dermal stem cells was screened out: 0.04-0.32 mg / mL. This concentration refers to the concentration of IGFBP-2 dissolved in pure aqueous solution.
[0020] (4) Based on the screening results of (3), human dermal stem cells were cultured in a culture medium containing 0.32 mg / mL IGFBP-2, and the mRNA expression levels of Rho GTPase pathway and Hippo / YAP pathway related indicators (RhoA, YAP) and melanin related indicators (TAZ, PAX3, MITF) were detected by qRT-PCR.
[0021] (5) Based on the screening results of (3), human dermal stem cells were cultured in a culture medium containing 0.32 mg / mL IGFBP-2. The morphology of dermal differentiated melanocytes was observed under an optical microscope, and the active form of RhoA, GTP-RhoA, was detected by the pull-down method. RhoA inhibitors were then used to observe whether the differentiation-promoting and melanogenesis-producing phenotypes could be reversed.
[0022] (6) Based on the screening results of (3), human dermal stem cells were cultured in a medium containing 0.32 mg / mL IGFBP-2, and the protein expressions of pYAP, total YAP, and nuclear and cytoplasmic YAP were detected by Western Blot. The distribution of YAP protein was detected by immunofluorescence, and YAP protein in human dermal stem cells was knocked down by shRNA, and Western Blot was used to detect whether the phenotype of promoting dermal stem cell differentiation and melanogenesis was reversed.
[0023] The experimental study of the present invention proves that IGFBP-2 can be used to prepare a drug for improving acrofacial vitiligo (i.e. acrofacial vitiligo repigmentation).
[0024] The medicine can be a clinical medicine for treating acrofacial vitiligo, and can also be used as a culture suspension in pigment transplantation surgery.
[0025] As a clinical drug, it can be applied externally (applied), usually twice a day, or injected, usually once a month;
[0026] Preliminary clinical trials of the drug showed that the effect of injecting autologous IGFBP-2 solution into the vitiligo of subjects' acrofacial leukoplakia (once a month) combined with conventional 308nm excimer phototherapy for vitiligo was significantly better than phototherapy alone.
[0027] The IGFBP-2 is used as a drug for re-pigmentation of acral vitiligo, and can be compounded with auxiliary materials such as hydrogel microspheres or hyaluronic acid to improve efficacy and convenience.
[0028] The suitable concentration of IGFBP-2 as a drug is 0.04-0.32 mg / mL, preferably 0.16-0.32 mg / mL, and more preferably 0.32 mg / mL.
[0029] The present invention provides a new method for improving acrofacial vitiligo by utilizing IGFBP-2. IGFBP-2 at a concentration of 0.04-0.32 mg / mL can promote the differentiation and melanogenesis of dermal stem cells without affecting the normal biological activity of human dermal stem cells, and depends on the RhoA / YAP signaling pathway. This indicates that IGFBP-2 can be used as a drug to safely and effectively improve the treatment resistance and difficulty in re-pigmentation of acrofacial vitiligo, and is suitable for the clinical treatment of depigmented skin diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 : The CCK-8 method was used to detect the effect of IGFBP-2 intervention on cell activity after 48 hours.
[0031] Figure 2 :IGFBP-2 affects the mRNA expression of Rho GTPase pathway, Hippo / YAP pathway and melanin-related indicators. Among them, (A) RhoA mRNA expression. (B) YAP mRNA expression. (C) TAZ mRNA expression. (D) PAX3 mRNA expression. (E) MITF mRNA expression.
[0032] Figure 3 :The effect of IGFBP-2 on cell morphology and active RhoA. Among them, (A) from top to bottom is the cell morphology observation of the control group, positive control PRP group and IGFBP-2 group. (B) Pull Down method was used to detect the expression of GTP-RhoA in the control group, positive control PRP group and IGFBP-2 group. (C) The detection results of three independent experiments are shown with mean±SD.
[0033] Figure 4:The effect of IGFBP-2 on the expression of pYAP and nuclear and cytoplasmic YAP proteins. Among them, (A) Western Blot detection of pYAP protein expression level when PRP and IGFBP-2 were not added, and PRP or IGFBP-2 was added alone. (B) The test results of three independent experiments are shown with mean±SD. (C) After separating the nuclear and cytoplasmic proteins, the expression of YAP protein was detected by Western Blot. (D) The test results of three independent experiments are shown with mean±SD.
[0034] Figure 5 :The effect of IGFBP-2 on YAP nuclear translocation under fluorescence microscopy. Among them, (A) from left to right are DAPI blue fluorescence nuclear staining, YAP yellow fluorescence nuclear staining, and the fusion of DAPI blue fluorescence and YAP yellow fluorescence; from top to bottom are the control group, IGFBP-2 group, and positive control PRP group. (B) The detection results of three independent experiments are shown with mean±SD.
[0035] Figure 6 :IGFBP-2 promotes dermal stem cell differentiation and melanogenesis dependent on the RhoA pathway. (A) Western Blot detection of differentiation and melanin-related protein expression after IGFBP-2 and Rhosin treatment. From left to right are the control group, IGFBP-2 group, IGFBP-2+Rhosin group and Rhosin group, from top to bottom are RhoA, YAP, TAZ, PAX3, MITF and GAPDH. (BF) The test results are expressed as mean±SD of three independent experiments.
[0036] Figure 7 :IGFBP-2 promotes dermal stem cell differentiation and melanogenesis dependent on YAP protein. Among them, (A) Western Blot detected the expression of differentiation and melanin-related proteins after IGFBP-2 and sh-YAP treatment. From left to right are the control group, IGFBP-2 group, Rhosin group and IGFBP-2+Rhosin group, from top to bottom are RhoA, YAP, TAZ, PAX3, MITF and GAPDH. (BF) The test results are expressed as mean±SD of three independent experiments.
[0037] Figure 8:The effect of IGFBP-2-rich solution on the repigmentation of acral vitiligo. Among them, (A) The right hand of a Fitzpatrick type III subject was in the PRP+308nm observation group. The clinical standard photos and corresponding white spot pictures under the Wood lamp during the follow-up period are the follow-up photography time from left to right: 1st, 2nd, 3rd, 4th, 5th, and 6th months. (B) The left hand of the subject was in the NS+308nm control group. (C) The VASI scores of the PRP+308nm observation group and the NS+308nm control group changed over time. (D) The VASI improvement rate of the PRP+308nm observation group and the NS+308nm control group changed over time. DETAILED DESCRIPTION
[0038] The present invention is further explained in conjunction with embodiments and corresponding drawings. The following embodiments are only for illustrative purposes and are not intended to limit the scope of the present invention.
[0039] Example 1: Effect of IGFBP-2 on the activity of human dermal stem cells
[0040] Culture of human dermal stem cells: Under sterile conditions, fresh foreskin tissue specimens were immersed in 75% ethanol for 30-60 seconds for disinfection, and then washed three times with PBS buffer containing 1% double antibody until blood was removed, each time for 3 minutes; under sterile conditions, ophthalmic scissors were used to carefully separate the subcutaneous connective tissue, and the foreskin tissue was trimmed into tissue fragments of about 2.5×2.5 mm in size. The fragments were placed in a DMEM solution of 0.025% DispaseⅡ and 10% FBS that had been prepared and filtered for bacteria, and stored in a 4°C refrigerator for digestion for 16-18 hours; ophthalmic forceps were used to transfer the tissue to PBS buffer + 1% double antibody for washing three times, each time for 3 minutes, and the dermis and epidermis were carefully separated to avoid confusing the ophthalmic forceps that contacted the dermis and epidermis, and the epidermis was discarded, and the dermis was immersed in 5mL 0.25% trypsin, and fully digested in a 37°C incubator for 2-3 hours; after digestion, 5mL containing 10% The digestion was terminated with FBS-containing DMEM solution, and the liquid was gently blown and mixed with a 1 mL pipette; the dermis was ground three times in different directions in a 100 μm cell mesh using a 1 mL syringe core to obtain a single-cell suspension, which was centrifuged at 1000 rpm for 3 min, and the supernatant was discarded to collect the cell precipitate; the cells were resuspended in the pre-configured DMEM / F12+B27+bFGF+EGF culture medium, and the cells were divided into T25 breathable culture flasks according to the number of cells, and 4 mL of culture medium was added to each flask. The cells were cultured in a cell culture incubator at 37°C and 5% CO2, and the cell medium was changed every 2-3 days; if the cells need to be prepared in a suspended state to form a three-dimensional spherical structure, the cells were placed in an ultra-low adsorption cell culture plate, and the cell medium was changed every 2-3 days.
[0041] Cell activity detection: Human dermal stem cells of the third generation in the logarithmic growth phase were selected and inoculated in a 96-well plate. The cell suspension volume was 100 μL / well and the cell density was about 1×10 4 cells / well, and set up a background control group (only culture medium, no cells), and place the 96-well plate in a 37°C, 5% CO2 incubator for 48 hours; when the cell confluence is close to 70-80%, different concentrations of IGFBP-2 intervention are given, the original cell culture medium in each well is aspirated and discarded, and the culture medium containing IGFBP-2 prepared in advance is added. At the same time, a blank control group (no culture medium and cells, only CCK-8 solution) is set up, with 3 replicates in each group, and placed in a 37°C, 5% CO2 incubator for 24 hours; take out the 96-well plate, add 10μL CCK-8 solution to each well, avoid bubbles when adding liquid to affect the detection of absorbance, and place the 96-well plate in a 37°C, 5% CO2 incubator for incubation for 1-4 hours; use an enzyme marker to detect the absorbance value at a wavelength of 450nm, and the value is preferably around 1.0. Finally, the cell viability calculation formula (%) = (each experimental group-background control group) / (blank control group-background control group) × 100%. The results are as follows Figure 1 The appropriate concentration of IGFBP-2 is 0.04-0.32 mg / mL.
[0042] Example 2: Effects of IGFBP-2 on Rho GTPase pathway, Hippo / YAP pathway and melanin-related indicators
[0043] Cell intervention conditions: Human dermal stem cells of the third generation in the logarithmic growth phase were seeded in 6-well plates at a cell density of approximately 1×10 6 cells / well, cultured at 37°C for 24h; cells were cultured in a culture medium containing 0.32mg / mL IGFBP-2 and other cytokines, respectively as the experimental group and the control group, with three replicate wells in each group; after culturing the cells at 37°C for 48h, cell samples were taken for experiments.
[0044] qRT-PCR experiment: Wash the bottom cells of the 6-well plate to be extracted with PBS, add 500μL Trizol lysis buffer to each well of cells, mix repeatedly by pipetting, and let stand at room temperature for 5 minutes; extract RNA; configure the reverse transcription system according to the instructions of the PrimeScriptTM RT MasterMix reverse transcription kit: 2μL 5X PrimeScript RT Master Mix + 500ng RNA sample, add DEPC water to make up to 10μL; place the configured sample in the PCR instrument, and set the reverse transcription program according to the instructions of the kit: 37℃, 15min, 85℃, 5s; 4℃, maintain; dilute the obtained cDNA sample 10 times; configure 10μL reaction system according to the instructions of the TB GreenPremix Ex TaqTMⅡ kit; place the configured sample in the QuantStudio6PCR instrument system for qRT-PCR amplification, and set the reaction program according to the instructions of the kit: Stage 1: number of cycles: 1, 95℃, 30s; Stage 2: number of cycles: 40, 95℃, 5s, 60℃, 34s. Based on this method, the corresponding primers of human RhoA, YAP, TAZ, PAX3, and MITF were selected for experiments to detect the mRNA expression of five indicators, RhoA, YAP, TAZ, PAX3, and MITF, in cells. Figure 2 As shown. (A) RhoA mRNA expression. (B) YAP mRNA expression. (C) TAZ mRNA expression. (D) PAX3 mRNA expression. (E) MITF mRNA expression. Compared with EGF, PDGF-AA, PDGF-AB, PDGF-BB, and SCF, IGFBP-2 can significantly upregulate the mRNA levels of Rho GTPase pathway, Hippo / YAP pathway, and melanin-related indicators in dermal differentiated melanocytes.
[0045] Example 3: Effects of IGFBP-2 on cell morphology and RhoA activity
[0046] Cell intervention conditions: the same as the “Cell intervention conditions” in “Example 2”.
[0047] Pull Down experiment: Magnetic bead incubation: Add an equal amount of lysate protein (800μg) to the pre-titrated rhotekin-RBD beads (50μg), incubate with shaking at 4℃ for 1h, and then centrifuge at 4000g for 1min at 4℃ to precipitate the rhotekin-RBD beads. Carefully remove 90% of the supernatant, taking care not to stir the beads, and wash once with 500μL of washing solution to ensure that the beads can be completely suspended. This process is completed within 1min, and then centrifuge the rhotekin-RBD beads at 4000g for 3min at 4℃, carefully remove the supernatant, and finally add 10μL 2×Laemmli sample buffer to each test tube, thoroughly resuspend the beads, and then boil the sample in a 99℃ metal bath for 2min. Based on this method, the active form of RhoA, GTP-RhoA, was selected for the experiment to detect the protein expression of GTP-RhoA in cells. The results are as follows Figure 3 As shown. IGFBP-2 can promote cell morphology and axonal extension (A), and significantly upregulate the expression level of active RhoA (B).
[0048] Example 4: Effect of IGFBP-2 on pYAP and nuclear and cytoplasmic YAP protein expression
[0049] Cell intervention conditions: the same as the “Cell intervention conditions” in “Example 2”.
[0050] Western Blot experiment: Total protein extraction: In a 6-well plate, wash the cells 3 times with PBS, discard the PBS, add 200 μL of strong RIPA containing 1 mM protease inhibitor and phosphatase inhibitor (added as needed) to the wells to lyse the cells, place the 6-well plate on an ice box, lyse the cells on a horizontal shaker for 30 minutes, scrape the cells completely and transfer them to an Eppendorf tube, centrifuge at 12500 rpm for 10 minutes at 4°C, aspirate the supernatant, and repeat once; Protein concentration determination: Protein quantification was performed using a BCA kit. First, a concentration gradient standard was prepared to obtain 0, 62.5, 125, 250, 500, 1000, 2000 μg / mL standard, then take 2 μL of the sample to be tested and 2 μL of the standard with different concentrations in a 96-well plate, mix the reaction reagents according to the ratio of A solution: B solution = 50:1, mix well, add 200 μL of staining reagent to each well, incubate at 37°C for 30 minutes, and finally detect the absorbance (OD value) at 565nm on a multifunctional microplate reader, and then draw a standard curve according to the concentration of BSA standard. Calculate the protein concentration of the sample; Sample preparation: Use RIPA to adjust the final concentration of each sample to 1μg / μL, add 5× Loading buffer, shake well to mix, heat in a 99℃ metal bath for 10min, spin, and place the sample on ice for loading; Electrophoresis: Remove the bottom gel strip from the 4-12% GenScript precast gel and install it in the electrophoresis instrument. Gently pull out the sample comb with both hands horizontally. The sample volume is 10-20μL / well for each sample. Add 6μL 1× Loading buffer to fill the protein marker of about 4μL, and add 10μL 1× Loading buffer to the remaining sample wells. Buffer was filled, voltage was set to 140V, and electrophoresis was performed for about 50 minutes; Western blotting: PVDF membrane was cut to be slightly larger than gel, PVDF equilibration solution was used to activate the membrane for 5 minutes, and the membrane was placed in transfer solution for later use. The upper left corner of the precast gel after electrophoresis was marked to clarify the position, and the precast gel was placed in the order of positive electrode-sponge-PVDF membrane-precast gel-sponge-negative electrode. The air bubbles between the membrane and gel were carefully removed with a roller, and the sandwich structure was placed in the transfer device, inserted to the bottom of the transfer instrument, and the corresponding standard transfer procedure was applied; Immunochromatography: The PVDF membrane was gently removed, and it could be stained with Ponceau red for 1 minute, and then stained with ddH 2O rinse, block with fast blocking solution at room temperature for 15 minutes, wash the blocked PVDF membrane with TBST prepared in advance for 3 times, 10 minutes each time, dilute the primary antibody in an appropriate ratio, incubate with shaking at 4°C overnight, discard the primary antibody on the second day, wash with TBST prepared in advance for 3 times, 10 minutes each time, dilute the secondary antibody in an appropriate ratio, incubate with shaking at room temperature for 1 hour, wash with TBST prepared in advance for 3 times, 10 minutes each time, and finally mix with ECL chemiluminescent solution in a 1:1 ratio in a dark room, remove the strips and drain, expose them through Tianneng scanner, detect protein information and collect pictures. Based on this method, the corresponding primary antibodies of human pYAP and YAP were selected for experiments to detect the protein expression of pYAP and YAP in cells. The results are as follows. Figure 4 As shown, IGFBP-2 can significantly upregulate the protein expression levels of pYAP and nuclear YAP.
[0051] Example 5: Effect of IGFBP-2 on YAP nuclear translocation
[0052] Cell intervention conditions: the same as the “Cell intervention conditions” in “Example 2”.
[0053] Immunofluorescence experiment: Fixation: discard the culture medium supernatant, wash 3 times with PBS buffer and then dry, add 100μL 4% paraformaldehyde to each well, fix at room temperature for 15-30min, and discard the 4% paraformaldehyde; Permeabilization: gently wash 3 times with PBS, 3min each time, discard the liquid in the well after washing, add 100μL 0.5% Triton X-100 to each well, permeabilize the cell membrane for 20min at room temperature, and discard the 0.5% Triton X-100; Blocking: gently wash 3 times with PBS, 3min each time, wipe the liquid in the well with clean absorbent paper after washing, and then add 5% Block with BSA for 30 min at room temperature, and discard the blocking solution; incubate with primary antibody: add 100 μL of primary antibody dilution to each well without washing, and incubate in a 4°C refrigerator overnight; incubate with secondary antibody: discard the primary antibody working solution, gently wash with PBS 3 times, 3 min each time, wipe the liquid with clean absorbent paper, and add 100 μL of fluorescent secondary antibody dilution (Alexa Fluor 555 dilution ratio is 1:200), incubate at room temperature in the dark for 1h, and discard the secondary antibody working solution; DAPI counterstaining: gently wash with PBS 3 times, 3min each time, wipe the liquid in the well with clean absorbent paper, add 100μL DAPI diluent (diluted with PBS buffer, dilution ratio: 1:10000) to each well, incubate at room temperature in the dark for 5min, and discard the DAPI diluent; observe and collect pictures under a fluorescence microscope: gently wash with PBS 3 times, 3min each time, wipe the liquid with clean absorbent paper, observe and collect pictures under a microscope, and repeat this experiment 3 times. Based on this method, the corresponding primary antibody of human YAP was selected for the experiment to detect the protein expression of YAP in the cell nucleus. The results are as follows Figure 5 As shown, this indicates that IGFBP-2 can promote the nuclear localization of YAP.
[0054] Example 6: IGFBP-2 promotes dermal stem cell differentiation and melanogenesis in a RhoA-dependent manner
[0055] Cell intervention conditions: Human dermal stem cells of the third generation in the logarithmic growth phase were seeded in 6-well plates at a cell density of approximately 1×10 6cells / well, cultured at 37℃ for 24h; 0.4μM Rhosin was used to inhibit RhoA to observe whether the phenotype of promoting differentiation and melanogenesis was reversed. The specific grouping is as follows. Control group: no intervention; IGFBP-2 group: IGFBP-2 was added at 0.32mg / mL; Rhosin group: Rhosin was added at 0.4μM; IGFBP-2+Rhosin group: IGFBP-2 and Rhosin were added at the same time. Three replicates were set up in each group; after culturing cells at 37℃ for 48h, cell samples were taken for experiments.
[0056] Western Blot experiment: The steps are the same as those in the “Western Blot experiment” in “Example 4”. Based on this method, the corresponding primary antibodies of human RhoA, YAP, TAZ, PAX3, and MITF were selected for experiments to detect the protein expression of RhoA, YAP, TAZ, PAX3, and MITF in cells. The results are shown in Figure 6 As shown, IGFBP-2 enhances the phenotype of promoting differentiation and melanogenesis, and inhibiting the RhoA pathway can reverse the effects of IGFBP-2 on promoting differentiation and melanogenesis to a certain extent. IGFBP-2 promotes dermal stem cell differentiation and melanogenesis dependent on the RhoA pathway.
[0057] Example 7: IGFBP-2 promotes dermal stem cell differentiation and melanogenesis dependent on YAP protein
[0058] Cell intervention conditions: Human dermal stem cells of the third generation in the logarithmic growth phase were seeded in 6-well plates at a cell density of approximately 1×10 6 cells / well, cultured at 37℃ for 24h; sh-YAP was used to knock down dermal stem cell YAP to observe whether its phenotype of promoting dermal stem cell differentiation and melanogenesis was reversed. The specific grouping is as follows. Control group: no intervention; IGFBP-2 group: IGFBP-2 added 0.32mg / mL; sh-YAP group: infected with sh-YAP virus; IGFBP-2+sh-YAP group: IGFBP-2 and sh-YAP virus were added at the same time. Three replicates were set up in each group; cell samples were taken for experiments after culturing cells at 37℃ for 48h.
[0059] Western Blot experiment: The steps are the same as those in the “Western Blot experiment” in “Example 4”. Based on this method, the corresponding primary antibodies of human RhoA, YAP, TAZ, PAX3, and MITF were selected for experiments to detect the protein expression of RhoA, YAP, TAZ, PAX3, and MITF in cells. The results are shown in Figure 7 As shown, this indicates that IGFBP-2 promotes dermal stem cell differentiation and melanogenesis phenotype in a YAP-dependent manner.
[0060] Example 8: Repigmentation test of acrofacial vitiligo with a solution rich in IGFBP-2
[0061] Clinical trial design: 20 patients with stable acrofacial vitiligo who visited Huashan Hospital in 2023 were selected for a single-center, self-controlled clinical trial. The patients had at least one stable skin lesion on the back of both hands, proximal fingers, distal fingers, and palms. Both hands were randomly divided into an experimental group and a control group. The experimental group received intradermal injection of IGFBP-2 solution once a month and 308nm excimer phototherapy twice a week, and the control group received the same frequency of saline injection and 308nm excimer phototherapy twice a week for 6 consecutive months. The evaluation index was the overall VASI score of the back and palm. The results are as follows: Figure 8 As shown, (A) The right hand of a Fitzpatrick type III subject was in the PRP+308nm observation group. The clinical standard photos and corresponding white spot pictures under the Wood lamp during the follow-up period are shown in the figure from left to right: 1st, 2nd, 3rd, 4th, 5th, and 6th months. (B) The left hand of the subject was in the NS+308nm control group. (C) The VASI scores of the PRP+308nm observation group and the NS+308nm control group changed over time. (D) The VASI improvement rate of the PRP+308nm observation group and the NS+308nm control group changed over time. The VASI score of the experimental group was significantly lower than that of the control group (0.24 vs 0.30, P = 0.045), and the VASI improvement rate was significantly increased (45.95 vs 30.10, P < 0.0001). The results suggest that the IGFBP-2-rich solution combined with 308nm excimer light is more effective in treating white spots on the back of the hand than phototherapy alone.
Claims
1. Use of IGFBP-2 in the preparation of drugs for repigmentation of acral vitiligo.
2. The use according to claim 1, It is characterized in that The medicine is a clinical medicine for treating acrofacial vitiligo, or is used as a culture suspension in pigment transplantation surgery.
3. The use according to claim 1 or 2, It is characterized in that IGFBP-2 does not affect the cell activity of human dermal stem cells at a safe concentration, and upregulates the expression of differentiation and melanogenesis-related proteins YAP, RhoA, TAZ, PAX3 and MITF. At the same time, IGFBP-2 effectively promotes the differentiation of dermal stem cells, which depends on the RhoA pathway and YAP.
4. The use according to claim 1 or 2, It is characterized in that The concentration of IGFBP-2 is 0.04-0.32 mg / mL.
